Funds will advance laru-zova toward commercialization for treatment of X-linked retinitis pigmentosa and accelerate development of additional pipeline candidates
LONDON and CAMBRIDGE, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (‘Beacon Therapeutics' or ‘the Company'), a leading clinical-stage biotechnology company with a mission to save and restore vision in people with rare and prevalent ocular diseases, today announced that it has raised over $75 million in an oversubscribed Series C financing led by Life Sciences at Goldman Sachs Alternatives and with participation from the Retinal Degeneration Fund (RD Fund), the venture arm of Foundation Fighting Blindness. Beacon's existing investors, Syncona Limited, Forbion, Oxford Science Enterprises, and Advent Life Sciences, also participated in the round.
"This significant fundraising, led by new blue-chip investor Life Sciences at Goldman Sachs Alternatives, validates our strategy to save and restore sight for people living with rare and prevalent ocular diseases," said Lance Baldo, MD, Chief Executive Officer of Beacon Therapeutics. "With pivotal laru-zova data expected in the second half of 2026, these funds will accelerate our commercial preparations for this potentially life-changing product, as well as advance and expand our pipeline. We thank our new and existing investors for their confidence in our mission to deliver lasting impact in blinding ocular diseases."
Beacon Therapeutics also appointed Colin Walsh, PhD, Managing Director, Life Sciences at Goldman Sachs Alternatives, to its Board of Directors.
"We are excited to work with Beacon Therapeutics at this critical time to ...
